Mizuho Securities Stick to Their Buy Rating for Iovance Biotherapeutics Inc By Investing.com – Investing.com

Mizuho Securities Stick to Their Buy Rating for Iovance Biotherapeutics Inc By Investing.com – Investing.com

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:) Inc on Tuesday, setting a price target of $55, which is approximately 113.01% above the present share price of $25.82.

Goldstein expects Iovance Biotherapeutics Inc to post earnings per share (EPS) of -$0.51 for the second quarter of 2021.

The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Iovance Biotherapeutics, with an average price target of $60.43.
The analysts price targets range from a high of $97 to a low of $50.